Skip to main content

Mintz To Support Life Sciences Start-Up Market Through Innovative Relationship With Nucleate Boston

BOSTON – Mintz has entered into an exclusive partnership with Nucleate Boston, providing the nonprofit organization with legal support for its 2023 Activator Program.

Nucleate’s Activator Program works with academic trainees to transform their science into successful companies. The program, since its inception, has supported over 100 early-stage venture teams and provides participants with access to its network, educational workshops, and with Mintz’s help in 2023, legal support. Member Joshua Fox will lead the Mintz team.

Mr. Fox said: “My practice focuses on representing entrepreneurs and start-ups in the life sciences industry, so it’s a great match for me to be collaborating with Nucleate. In addition, I am excited to be working with the start-ups that are part of Nucleate and look forward to helping the entrepreneurs and founders that are part of the program.

“Mintz is a leading law firm in the biotech space, advising companies on corporate transactions, intellectual property, regulatory matters and litigation, so this partnership makes perfect sense for us as a firm.” 

Nucleate’s 2023 Activator Program began in January and will support over 100 new ventures worldwide with 17 teams in the Boston Chapter. Activator teams will participate in hands-on workshops and receive mentorship from industry experts throughout the program, culminating in a final pitch showcase.

Mintz, a leading life sciences law firm, represents therapeutics, vaccine, medical device and systems, research tools and diagnostics companies, as well as investment banks, venture capital firms and other investors. Our work for these clients encompasses transactional, health care regulatory, intellectual property, litigation, employment, real estate and other matters. We are embedded in the global life sciences ecosystem and provide industry leaders with practical solutions to business-critical challenges, helping them achieve their strategic and business goals.

  • $22 billion+ in transactions handled in 2021 for industry clients, including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings
  • Advise on the complete spectrum of FDA regulations, from clinical trials through product launch and beyond, including product approvals, labeling, and supply and distribution agreements
  • Prosecute patents to issuance (more than 30 patent team members have biology or chemistry PhDs), navigate trademarks through the USPTO and health regulatory bodies, and defend patent, trade secret and trademark rights in trial courts and at the USPTO
  • Successful track record of helping life sciences clients avoid — and when necessary resolve —securities class actions, governmental investigations, and disputes with collaboration/licensing partners

To learn more about our life sciences practice, please visit

About Nucleate

Nucleate is a nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 18 geographic regions and participation from over 120 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit for more information, and email [email protected] if you want to get involved with our programming.